SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001305253-22-000008
Filing Date
2022-11-03
Accepted
2022-11-03 16:36:11
Documents
62
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q eigr-20220930.htm   iXBRL 10-Q 1631519
2 EX-31.1 eigr-2022x09x30ex311.htm EX-31.1 9802
3 EX-31.2 eigr-2022x09x30ex312.htm EX-31.2 9785
4 EX-32.1 eigr-2022x09x30ex321.htm EX-32.1 5406
  Complete submission text file 0001305253-22-000008.txt   6604092

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eigr-20220930.xsd EX-101.SCH 45592
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT eigr-20220930_cal.xml EX-101.CAL 68731
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT eigr-20220930_def.xml EX-101.DEF 186818
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eigr-20220930_lab.xml EX-101.LAB 555615
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eigr-20220930_pre.xml EX-101.PRE 347981
56 EXTRACTED XBRL INSTANCE DOCUMENT eigr-20220930_htm.xml XML 1025982
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 221358631
SIC: 2836 Biological Products, (No Diagnostic Substances)